Skip to Main Content

Author Details

Eric Vigneault
Centre Hospitalier Universitaire de Quebec
1997
99
28
PMIDPaper TitleJournal TitlePublished Year
37806788US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment.Brachytherapy2024
36191741GEC-ESTRO (ACROP)-ABS-CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina.Int J Radiat Oncol Biol Phys2023
37863069A Monte Carlo dose recalculation pipeline for durable datasets: an I-125 LDR prostate brachytherapy use case.Phys Med Biol2023
37059334Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study.Radiother Oncol2023
37080858Infection after prostatic transrectal fiducial marker implantation for image guided radiation therapy.Cancer Radiother2023
37137444Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys2023
36875870Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial.Clin Transl Radiat Oncol2023
32594313Mapping the Current State of Canadian Medical School Oncology Interest Groups.J Cancer Educ2022
35585019Inter-observer evaluation of a GPU-based multicriteria optimization algorithm combined with plan navigation tools for HDR brachytherapy.Brachytherapy2022
366566942022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.Can Urol Assoc J2022
36494834Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial.Radiat Oncol2022
363785722022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).Can Urol Assoc J2022
34919884Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.Int J Radiat Oncol Biol Phys2022
35233228Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning.J Contemp Brachytherapy2022
34740768Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).Int J Radiat Oncol Biol Phys2022
33186617Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.Int J Radiat Oncol Biol Phys2021
33901566Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys2021
335563132021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).Can Urol Assoc J2021
34272132Commissioning of an intra-operative US guided prostate HDR system integrating an EM tracking technology.Brachytherapy2021
34238688PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study.Brachytherapy2021
33279855Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.Eur J Cancer2021
32374715A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association.Can Urol Assoc J2020
31999544Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.Can Urol Assoc J2020
32713779Evaluating the impact of real-time multicriteria optimizers integrated with interactive plan navigation tools for HDR brachytherapy.Brachytherapy2020
32928485Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.Brachytherapy2020
32201973DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.Prostate2020
30312717A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).Int J Radiat Oncol Biol Phys2019
31673656A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer.Adv Radiat Oncol2019
31548819Employment outcomes for recent Canadian radiation oncology graduates.Curr Oncol2019
316034092019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).Can Urol Assoc J2019
31230941MRI-based interstitial brachytherapy for vaginal tumors: A multi-institutional study on practice patterns, contouring, and consensus definitions of target volumes.Brachytherapy2019
31444133The association of intraprostatic calcifications and dosimetry parameters with biochemical control after permanent prostate implant.Brachytherapy2019
31039422National Trends and Dynamic Responses in the Canadian Radiation Oncology Workforce From 1990 to 2018.Int J Radiat Oncol Biol Phys2019
30935583Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes.Radiother Oncol2019
28576644Real-time electromagnetic tracking-based treatment platform for high-dose-rate prostate brachytherapy: Clinical workflows and end-to-end validation.Brachytherapy2018
30238902In Regard to Bossi et al.Int J Radiat Oncol Biol Phys2018
30212298The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines.J Clin Oncol2018
29903505Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).Clin Oncol (R Coll Radiol)2018
29543933Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.JAMA Oncol2018
29428250Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?Int J Radiat Oncol Biol Phys2018
27780694Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.Clin Oncol (R Coll Radiol)2017
28455849Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.Med Phys2017
28333001The Practice of Radiation Oncology in Canada.Int J Radiat Oncol Biol Phys2017
28126308Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.Int J Radiat Oncol Biol Phys2017
29106365Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population.Can Urol Assoc J2017
28652094High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes.Radiother Oncol2017
28807532Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.Int J Radiat Oncol Biol Phys2017
28777690Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.J Clin Oncol2017
26782838Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.Clin Oncol (R Coll Radiol)2016
27790388Image-Guided High-Dose-Rate (HDR) Boost Localization Using MRI/MR Spectroscopy: A Correlation Study with Biopsy.Cureus2016
  • 1 - 50 of 99

Recommended Authors

Audrey Dang
Tulane University School of Medicine
Career Start Year 2018
Number of shared co-authors 8
Robert T Dess
University of Michigan ann arbor
Career Start Year 2016
Number of shared co-authors 21
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 11
Ryan Fiano
Urologic Research Institute, Ohio University School of Medicine
Career Start Year 2013
Number of shared co-authors 11
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 13
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 7
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 11
Amar U Kishan
University of California los angeles
Career Start Year 2008
Number of shared co-authors 23
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 15
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 14
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 4
Neil B Desai
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 12
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 17
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 1
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 14
Danny Y Song
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 13
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 20
Brian J Moran
Chicago Prostate Cancer Center
Career Start Year 1999
Number of shared co-authors 14
Gregory S Merrick
Urologic Research Institute, Ohio University School of Medicine
Career Start Year 1997
Number of shared co-authors 15
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 10
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 1996
Number of shared co-authors 8
Michael L Steinberg
University of California los angeles
Career Start Year 1996
Number of shared co-authors 19
Jay P Ciezki
Cleveland Clinic
Career Start Year 1995
Number of shared co-authors 15
Almudena Zapatero
University Hospital La Princesa
Career Start Year 1995
Number of shared co-authors 17
Patrick A Kupelian
university of california los angeles Medical Center
Career Start Year 1993
Number of shared co-authors 18
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 15
Richard G Stock
Icahn School of Medicine at Mount Sinai
Career Start Year 1992
Number of shared co-authors 14
Richard Choo
Mayo Clinic
Career Start Year 1991
Number of shared co-authors 14
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 12
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Career Start Year 1986
Number of shared co-authors 8

Collaborators

Mack Roach
University of California San Francisco
Co-authored papers 8
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 8
Andr?? Fortin
Laval University, CHU de Quebec
Co-authored papers 6
Michael Brundage
Cancer Centre of Southeastern Ontario
Co-authored papers 6
Neil E Fleshner
University of Toronto
Co-authored papers 6
Fred Saad
University of Montreal Health Center
Co-authored papers 6
Kim N Chi
University of British Columbia
Co-authored papers 6
Jeff M Michalski
Washington University School of Medicine
Co-authored papers 6
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Co-authored papers 5
Antonio Finelli
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Co-authored papers 5
Andrew Warner
Western University and London Regional Cancer Program
Co-authored papers 4
Fran??ois Meyer
Laval University
Co-authored papers 4
Isabelle Bairati
Laval University Cancer Research Center
Co-authored papers 3
Armen Aprikian
McGill University Health Centre, McGill University
Co-authored papers 3
Mitchell Kamrava
Cedars Sinai Medical Center
Co-authored papers 3
Martin E Gleave
University of British Columbia
Co-authored papers 3
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 3
Albert J Chang
University of California Los Angeles
Co-authored papers 2
William L Barrett
Department of Radiation Oncology University of Cincinnati Cincinnati Ohio USA.
Co-authored papers 2
Deborah W Bruner
Emory University, USA Winship Cancer Institute, USA School of Medicine
Co-authored papers 2
Robert Ivker
Prostate Cancer Center of New Jersey.
Co-authored papers 2
Daniel J Krauss
William Beaumont School of Medicine
Co-authored papers 2
Michael Milosevic
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Christopher U Jones
Sutter Medical Center Sacramento
Co-authored papers 2
David I Rosenthal
MD Anderson Cancer Center
Co-authored papers 2
Brian J Davis
Mayo Clinic
Co-authored papers 2
Thomas M Pisansky
Mayo Clinic
Co-authored papers 2
Bernard T??tu
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Co-authored papers 2
Stephanie L Pugh
Co-authored papers 1
Abul Kalam Azad
University of Dhaka
Co-authored papers 1
Release 1.2